J. Mann

发表

Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial.

J. Tardif, M. Guertin, J. Tanguay, 2013, Journal of the American College of Cardiology.

Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure

J. McMurray, D. Murdoch, T. McDonagh, 2007, European journal of heart failure.

Pharmacokinetics and Dosage Recommendations for an Oseltamivir Oral Suspension for the Treatment of Influenza in Children

P. Ward, R. Dutkowski, C. Oo, 2001, Paediatric drugs.

Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases.

P. Fontana, K. Sakariassen, H. Bounameaux, 2009, Future cardiology.

Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine

P. Palatini, F. Dorigatti, S. Di Somma, 2001, European Journal of Clinical Pharmacology.

Effects of valsartan on left ventricular diastolic function in patients with mild or moderate essential hypertension: comparison with enalapril.

B. Trimarco, R. Izzo, A. Cuocolo, 1999, Journal of hypertension.

Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT‐ACS Trial

J. Tardif, M. Guertin, J. Tanguay, 2016, Journal of the American Heart Association.

Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial.

M. Carrier, J. Tardif, M. Guertin, 2016, Journal of the American College of Cardiology.

Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine.

W. Dieterle, J. Mann, S. Corynen, 2005, International journal of clinical pharmacology and therapeutics.

Pharmacokinetics and Pharmacodynamics of the ETA‐Selective Endothelin Receptor Antagonist SPP301 in Healthy Human Subjects

W. Dieterle, J. Mann, K. Kutz, 2004, Journal of clinical pharmacology.

Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects.

W. Dieterle, J. Mann, S. Corynen, 2004, British journal of clinical pharmacology.

Pharmacokinetics and pharmacodynamics of benazepril hydrochloride in patients with major proteinuria

C. Schweizer, W. Dieterle, G. Kaiser, 2004, European Journal of Clinical Pharmacology.

The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.

S. Julius, J. Mann, 1998, Blood pressure.

Influence of avosentan (SPP3OI) on the pharmacokinetics of a second generation oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.

W. Dieterle, J. Mann, 2006, International journal of clinical pharmacology and therapeutics.

Multiple-dose pharmacokinetics, pharmacodynamics and tolerability of the oral ET(A) endothelin-receptor antagonist SPP301 in man.

W. Dieterle, J. Mann, K. Kutz, 2005, International journal of clinical pharmacology and therapeutics.